Article

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France.
Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association (Impact Factor: 7.9). 06/2008; 6(6):644-53. DOI: 10.1016/j.cgh.2008.03.014
Source: PubMed

ABSTRACT

We performed a meta-analysis of placebo-controlled trials to evaluate safety and efficacy of tumor necrosis factor (TNF) antagonists for Crohn's disease.
We searched MEDLINE, Cochrane Library, and EMBASE. The primary end points were clinical remission for luminal Crohn's disease and fistula closure at > or =2 consecutive visits. Deaths, serious infections, and malignancies were also analyzed by the methods of Peto and Der Simonian and Laird.
Fourteen luminal Crohn's disease trials enrolled 3995 patients. In overall analysis, anti-TNF therapy was effective for induction of remission at week 4 (mean difference, 11%; 95% confidence interval [CI], 6%-16%; P < .001) and maintenance of remission at weeks 20-30 in patients who responded to induction therapy and in patients randomized before induction (mean difference, 23%; 95% CI, 18%-28% and mean difference, 8%; 95% CI, 3%-12%, respectively; P < .001 for all comparisons). Ten studies evaluated anti-TNF for treatment of fistulizing Crohn's disease, involving 776 patients. In overall analysis, anti-TNF therapy was effective for fistula closure only in maintenance trials after open-label induction (mean difference, 16%; 95% CI, 8%-25%; P < .001). In 21 studies enrolling 5356 individuals, anti-TNF therapy did not increase the risk of death, malignancy, or serious infection.
Infliximab, adalimumab, and certolizumab are effective in luminal Crohn's disease. Efficacy of anti-TNF agents other than infliximab in treating fistulizing Crohn's disease requires additional investigations. A longer duration of follow-up and a larger number of patients are required to better assess the safety profile of TNF antagonists in Crohn's disease.

Download full-text

Full-text

Available from: Pierre Deltenre
  • Source
    • "We briefly discuss the recent data available on infliximab biosimilars in IBD, proposing the best patient profile to be eligible for the use of biosimilars in the next future. In the last two decades, monoclonal antibodies (mAb), also known as biological agents, have brought a revolution in the management of inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, in terms of controlling disease symptoms, healing mucosal lesions, and reducing the IBD-related hospitalization and surgery rates[1,2]. Costs derived from the use of mAb account for the 15% of all costs related to IBD in the first year[3], and they are expected to increase in the next future, also considering that up to 50% of patients achieving deep remission with mAb would need to continue biological agents overtime. "

    Preview · Article · Jan 2016 · Expert Review of Clinical Immunology
  • Source
    • "Data from the GEMINI CD studies have shown that VDZ is effective in promoting fistula closure in 46% of patients compared to 11% in the placebo arm[48,49]. However, contrary to previous experience with IFX[90], no study evaluated the efficacy and safety of VDZ after surgery in such patient group. Summary of recommendations – Fistulizing CD may be treated by a combination of surgical treatment and IFX infusions (EL1c RGA). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic, relapsing conditions resulting from uncontrolled inflammation of the intestinal mucosa. Both conditions are associated with significant disability and patients with CD face higher mortality rates compared to the general population. The increasing understanding of the immunological basis of the disease led to the introduction of biologic therapies targeting key pathways of the natural and adaptive immune response such as Tumor Necrosis Factor α (TNF-α) inhibitors and, more recently, integrin-receptor antagonists. Treatment with TNF-α inhibitors improved clinical and patient-reported outcomes for many patients who did not benefit from conventional therapy. However, a sizeable share of patients still face suboptimal outcomes due to primary or secondary therapy failure. With the introduction of VDZ, a biologic treatment targeting novel IBD-relevant biologic pathways, it is crucial to understand how to integrate such innovations into current clinical practice. To this end, a panel of 14 Italian experts in the management of IBD met for a roundtable discussion. Recommendations concerning the management of moderate-to-severe IBD based on experts’ opinions and literature review are discussed in the present report.
    Full-text · Article · Jan 2016
  • Source
    • "Anti-TNF therapy is at present the most effective, but also the most costly therapy for IBD. The most frequently used anti-TNF therapies, infliximab and adalumimab, have a sustained response rate of between 21 and 48% [82] [83]. Because of the extremely high costs of these drugs a test that could predict their effectiveness would be highly lucrative. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory bowel disease, consisting of Crohn’s disease and ulcerative colitis, is a chronic inflammatory disease of the gut, which arises through an excessive immune response to the normal gut flora in a genetically susceptible host. The disease affects predominantly young adults and due to its chronic and relapsing nature gives rise to a high disease burden both financially, physically and psychologically. Current therapy still cannot prevent the need for surgical intervention in more than half of IBD patients. Consequently, advances in IBD therapy are of high importance. Recently, several new forms of targeted therapy have been introduced, which should improve surgery-free prognosis of IBD patients. Recent identification of genetic risk variants for IBD has led to new insights into the biological mechanisms of the disease, which will, in the future, lead to new targeted therapy. In the meantime repositioning of drugs from biologically similar diseases towards IBD might lead to new IBD therapies.
    Preview · Article · Jun 2014 · Baillière&#x027 s Best Practice and Research in Clinical Gastroenterology
Show more